13826-35-2Relevant academic research and scientific papers
Ullman Ether Synthesis in DMI. Preparation of m-Phenoxybenzyl Alcohol
Oi, Ryu,Shimakawa, Chitoshi,Takenaka, Shinji
, p. 899 - 900 (1988)
The condensation of m-hydroxybenzyl alcohol with chlorobenzene was examined in several different solvents, and an effective route to m-phenoxybenzyl alcohol has been developed by using 1,3-dimethyl-2-imidazolidinone (DMI) as a solvent.
KF-Al2O3 mediated cross-Cannizzaro reaction under microwave irradiation
Subba Reddy,Srinivas,Yadav,Ramalingam
, p. 219 - 223 (2002)
Aromatic aldehydes are selectively converted to the corresponding alcohols in high yields by cross-Cannizzaro reaction using KF-Al2O3 under microwave irradiation in solvent-free condition.
Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists
Liu, Chunxia,Li, Zheng,Shi, Wei,Li, Huilan,Wang, Nasi,Dai, Yuxuan,Liao, Chen,Huang, Wenlong,Qian, Hai
, p. 1547 - 1554 (2018)
The free fatty acid receptor 1 (FFA1) is a potential target due to its function in enhancing of glucose-stimulated insulin secretion. The FFA1 agonist GW9508 has great potential for the treatment of type 2 diabetes mellitus, but it has been suffering from high plasma clearance probably because the phenylpropanoic acid is vulnerable to β-oxidation. To identify orally available analog without influence on the unique pharmacological mechanism of GW9508, we tried to interdict the metabolically labile group by incorporating two deuterium atoms at the α-position of phenylpropionic acid affording compound 4 (HWL-066). As expected, HWL-066 revealed a lower clearance (CL?=?0.23?L?1?hr?1?kg?1), higher maximum concentration (Cmax?=?5907.47?μg/L), and longer half-life (T1/2?=?3.50?hr), resulting in a 2.8-fold higher exposure than GW9508. Moreover, the glucose-lowering effect of HWL-066 was far better than that of GW9508 and comparable with TAK-875. Different from glibenclamide, no side-effect of hypoglycemia was observed in mice after oral administrating HWL-066 (80?mg/kg).
Thermal decomposition and isomerization of cis-permethrin and β-cypermethrin in the solid phase
Audino, Paola Gonzalez,Licastro, Susana A.,Zerba, Eduardo
, p. 183 - 189 (2002)
The stability to heat of cis-permethrin and β-cypermethrin in the solid phase was studied and the decomposition products identified. Samples heated at 210°C in an oven in the dark showed that, in the absence of potassium chlorate (the salt present in smoke-generating formulations of these pyrethroids), cis-permethrin was not isomerized, although in the presence of that salt, decomposition was greater and thermal isomerization occured. Other salts of the type KXO3 or NaXO3, with X being halogen or nitrogen, also led to a considerable thermal isomerization. Heating the insecticides in solution in the presence of potassium chlorate did not produce isomerization in any of the solvents assayed. Salt-catalysed thermal cis-trans isomerization was also found for other pyrethroids derived from permethrinic or deltamethrinic acid but not for those derived from chrysanthemic acid. The main thermal degradation processes of cis-permethrin and β-cypermethrin decomposition when potassium chlorate was present were cyclopropane isomerization, ester cleavage and subsequent oxidation of the resulting products. Permethrinic acid, 3-phenoxybenzyl chloride, alcohol, aldehyde and acid were identified in both cases, as well as 3-phenoxybenzyl cyanide from β-cypermethrin. A similar decomposition pattern occurred after combustion of pyrethroid fumigant formulations.
Phenylpropiolic acid small molecular organic compounds and synthetic method and application thereof
-
Paragraph 0070; 0071; 0072, (2019/04/13)
The invention relate to a category of novel phenylpropiolic acid small molecular organic compounds as shown in a structural formula (I) or stereisomers, crystals, hydrates or pharmaceutically acceptable salt and an application of the phenylpropiolic acid small molecular organic compounds or stereisomers, crystals, hydrates or pharmaceutically acceptable salt and pharmaceutical compositions comprising the compounds in preparing a GPR40 agonist and drugs for promoting insulin release, treating and/or preventing diabetes or complications, treating diabetes inducing poor therapeutic effect inducedby acquired drug-resistance and complications and the like. The invention also provides a preparation method of the phenylpropiolic acid small molecular organic compounds as shown in the structural formula (I). The phenylpropiolic acid small molecular organic compounds have good anti-diabetes effect and the risk of inducing hypoglycemia is lower than that of conventional drugs.
IMPROVED METHOD FOR THE SYNTHESIS OF PERMETHRIN
-
Page/Page column 7; 8, (2018/03/25)
The present invention describes an improved method for the synthesis of substantially pure Permethrin (1) having purity greater than 99.5% by Gas Chromatography (GC). The invention also relates to a purification process of Permethrin by recrystallization from methanol-water mixture.
Methanol as hydrogen source: Transfer hydrogenation of aromatic aldehydes with a rhodacycle
Aboo, Ahmed H.,Bennett, Elliot L.,Deeprose, Mark,Robertson, Craig M.,Iggo, Jonathan A.,Xiao, Jianliang
supporting information, p. 11805 - 11808 (2018/11/10)
A cyclometalated rhodium complex has been shown to perform highly selective and efficient reduction of aldehydes, deriving the hydrogen from methanol. With methanol as both the solvent and hydrogen donor under mild conditions and an open atmosphere, a wide range of aromatic aldehydes were reduced to the corresponding alcohols, without affecting other functional groups.
Novel deuterated phenylpropionic acid derivative, preparation method thereof, and use of derivative as medicine
-
, (2017/10/07)
The invention relates to a novel deuterated phenylpropionic acid derivative represented by general formula (I), a preparation method thereof, and a use of a medicinal composition containing the derivative as a medicine for treating diabetes and metabolic syndrome. The deuterated phenylpropionic acid derivative has excellent in vivo blood sugar lowering activity, and can be used for preparing medicines for preventing or treating diabetes.
Copper-Catalyzed Diaryl Ether Formation from (Hetero)aryl Halides at Low Catalytic Loadings
Zhai, Yuntong,Chen, Xiaofei,Zhou, Wei,Fan, Mengyang,Lai, Yisheng,Ma, Dawei
, p. 4964 - 4969 (2017/05/12)
Diaryl formation is achieved by coupling phenols and (hetero)aryl halides under the catalysis of CuI/N,N′-bis(2-phenylphenyl) oxalamide (BPPO) or CuI/N-(2-phenylphenyl)-N′-benzyl oxalamide (PPBO) at 90 °C using DMF or MeCN as the solvent. Only 0.2-2 mol % CuI and ligand are required for complete conversion, which represents the lowest catalytic loadings for a general Cu/ligand-catalyzed diaryl ether formation.
CuI/oxalamide catalyzed couplings of (hetero)aryl chlorides and phenols for diaryl ether formation
Fan, Mengyang,Zhou, Wei,Jiang, Yongwen,Ma, Dawei
supporting information, p. 6211 - 6215 (2016/05/24)
Couplings between (hetero)aryl chlorides and phenols can be effectively promoted by CuI in combination with an N-aryl-N′-alkyl-substituted oxalamide ligand to proceed smoothly at 120 °C. For this process, N-aryl-N′-alkyl-substituted oxalamides are more effective ligands than bis(N-aryl)-substituted oxalamides. A wide range of electron-rich and electron-poor aryl and heteroaryl chlorides gave the corresponding coupling products in good yields. Satisfactory conversions were achieved with electron-rich phenols as well as a limited range of electron-poor phenols. Catalyst and ligand loadings as low as 1.5 mol % are sufficient for the scaled-up variants of some of these reactions. Aryl and alkyl: N-Aryl-N′-alkyl-substituted oxalamide ligands promote the CuI catalyzed coupling of (hetero)aryl chlorides and phenols at 120 °C more effectively than bis(N-aryl)-substituted oxalamides. A wide range of electron-rich and electron-poor aryl and heteroaryl chlorides were converted into the corresponding coupling products in good yields.
